Nodality, Inc. Launches PathPro Chronic Lymphocytic Leukemia (CLL) Panels Based On Leading Single Cell Network Profiling (SCNPTM) Platform To Enhance Pharmaceutical R&D

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Nodality, Inc., which is focused on solving drug development challenges, announced today the availability of its new PathPro™ Chronic Lymphocytic Leukemia (CLL) panels. These panels are designed to characterize cell pathways associated with disease signaling at the single cell level and to analyze the activity of therapeutics commonly used or in development to treat CLL. Earlier this year, Nodality introduced its first PathPro products, which leverage the unique capabilities of Nodality’s proprietary multiparametric flow cytometry platform to study the functional activity of customer therapeutics and identify disease subgroups and differential activities in pathways or diseases. In addition to the PathPro CLL panels, Nodality has launched the PathPro JAK-STAT, PathPro TLR, and the PathPro AML panels. The Company anticipates additional PathPro product launches in 2015.

Help employers find you! Check out all the jobs and post your resume.